The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies

Luque‐Ramírez, Manuel; Carreño, Ágata; Escolá, Cristina Álvarez; Picó, Carlos del Pozo; Costa, César Varela da; Montañana, Carmen Fajardo; Gilabert, Montserrat; Webb, Susan M.

doi:10.1016/j.endoen.2011.09.001

Cited by 4 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59 A review of data from registry studies shows that the majority of patients with acromegaly do not achieve disease control. 30,32,58 There remains a need for improved definition of disease control in…”

Section: Resultsmentioning

confidence: 99%

“…Several registry studies indicate that the effectiveness of treatment in actual clinical practice is significantly lower than those reported in clinical trials. 30,32,58 Registry studies, however All patients received octreotide 100 µg three times daily (tid) for one month followed by one month of pasireotide 200, 400, or 600 µg twice daily (bid). Results after one month octreotide and one month octreotide plus one month pasireotide are presented here.…”

Section: Treatment Effectiveness In Clinical Practicementioning

confidence: 99%

“…However, of the patients receiving first-line medical treatment, only 22 % had disease control at the end of follow-up. 58 Results from the Spanish acromegaly registry (n=1,219) showed that, of 113 patients who received first-line drug treatment to control the disease, only 7.1 % achieved disease control. Of 277 patients who received surgery and drugs, 35.7 % achieved disease control.…”

Section: Treatment Effectiveness In Clinical Practicementioning

confidence: 99%

See 2 more Smart Citations

Are We Achieving Pharmacological Disease Control in Acromegaly?

Colao¹

2010

European Endocrinology

View full text Add to dashboard Cite

Acromegaly is a rare endocrine disorder, associated with significant morbidity and mortality due to the harmful effects of prolonged exposure to increased levels of growth hormone (GH) and its effector, insulin-like growth factor-1 (IGF-1). The most common cause of acromegaly is a pituitary adenoma, for which surgical resection is usually the first choice treatment. In cases where surgical resection is not possible, or where the patient declines surgery, somatostatin analogues (SSAs) are used as first-line medical therapy. Other therapeutic options include dopamine antagonists and the GH receptor antagonist – pegvisomant. In addition, considerable current research is investigating the clinical utility of combined therapies. Disease control is defined in terms of reduction of GH and IGF-1 normalisation and reduction in mortality levels to those seen in the general population. Reported disease control rates of acromegaly are highly variable and it has been reported that treatment efficacy in clinical practice is considerably lower than the success rates reported by reference centres. There is therefore a substantial need for improved disease management strategies for acromegaly.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Treatment Effectiveness In Clinical Practicementioning

confidence: 99%

Section: Treatment Effectiveness In Clinical Practicementioning

confidence: 99%

See 1 more Smart Citation

Are We Achieving Pharmacological Disease Control in Acromegaly?

Colao¹

2010

European Endocrinology

View full text Add to dashboard Cite

show abstract

“…1,2 In Spain, there is a prevalence of approximately 60 cases per million, but estimates vary between 15.7 and 75.8 in different regions. [3][4][5] Three drug classes are available for medical therapy: somatostatin analogues (SSA), dopamine agonists, and GH receptor antagonists, namely pegvisomant. 1,2 SSAs, such as lanreotide or octreotide are administered as first-line therapy or as second-line therapy in patients undergoing unsuccessful surgery and are currently considered a cornerstone in the treatment of acromegaly.…”

Section: Introductionmentioning

confidence: 99%

Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Puig-Domingo

Soto

Venegas

et al. 2016

Endocrinología y Nutrición (English Edition)

View full text Add to dashboard Cite

show abstract

“…In Europe, the annual incidence of clinically diagnosed acromegaly was estimated in the past at 3 to 4 per million and the prevalence at 35–70 per million . The peak incidence of the disease occurs in middle age, with more women affected (61%) than men, and there is a substantial delay between occurrence of the first symptoms and diagnosis …”

Section: Introductionmentioning

confidence: 99%

Treatment of acromegaly in the era of personalized and predictive medicine

Puig-Domingo

2015

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Acromegaly is a chronic disorder usually diagnosed late in the disease evolution. Such delayed diagnosis, together with the inability to achieve the treatment goals of normalizing biochemical disease markers and controlling tumour mass may result in substantial morbidity and mortality. Somatostatin analogues (SSA) are accepted as first‐line medical therapy or as second‐line therapy in patients undergoing unsuccessful surgery and are considered a cornerstone in the treatment of acromegaly. However, because a high percentage of patients experience SSA medical treatment failure, the identification of biomarkers associated with a successful or unsuccessful response to all classes of medical therapy would help in the choice of treatment and potentially allow for a quicker normalization of biochemical parameters. The current treatment algorithms for acromegaly are based upon a “trial‐and‐error” approach with additional treatment options provided when disease is not controlled. In many other diseases, therapeutic algorithms have been evolving towards personalized treatment with the medication that best matches individual disease characteristics, using biomarkers that identify therapeutic response. Additionally, a personalized approach to complementary treatment of comorbidities present in the acromegalic patient is also required. This review will discuss the development of a potential treatment algorithm for acromegaly addressing the biochemical control of the disease as well of its associated comorbidities, under a personalized approach based upon markers of prognostic and predictive significance, such as tumour size, MRI adenoma signal, GH value after acute octreotide test, granular adenoma pattern, Ki‐67, somatostatin receptor phenotype, aryl hydrocarbon‐interacting protein expression, gsp mutations, RAF kinase activity, E‐cadherin and beta‐arrestin‐1.

show abstract

The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies

Cited by 4 publications

References 34 publications

Are We Achieving Pharmacological Disease Control in Acromegaly?

Are We Achieving Pharmacological Disease Control in Acromegaly?

Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Treatment of acromegaly in the era of personalized and predictive medicine

Contact Info

Product

Resources

About